Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

76.17 +0.41 (+0.53%)
Streaming Delayed Price Updated: 3:04 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Top Analyst Reports For AstraZeneca, Qualcomm & FedEx
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX​​​​​​​). 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
From AstraZeneca
Via Business Wire
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and potential... 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Double Good News For AstraZeneca's Breast Cancer Drugs
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
Via Benzinga
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Why Quality-Oriented Investors Should Consider NASDAQ:AZN. 
Via Chartmill
Looking At AstraZeneca's Recent Unusual Options Activity
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
From AstraZeneca
Via Business Wire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Top 4 Health Care Stocks That May Plunge This Month
Via Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
AZN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal... 
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
Q1 2024 results
From AstraZeneca
Via Business Wire
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth. 
Via InvestorPlace
European Stock: AstraZeneca
AstraZeneca PLC is a science-led biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and... 
Via Talk Markets
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
Exposures Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
These are the undervalued blue-chip stocks for inflation protection, with the Fed likely to delay the first interest rate cut. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.